

Country-Level 90-90-90 Targets, Progress and Experiences

National HIV/AIDS Program

Dra. Alethse De la Torre Rosas
General Director CENSIDA



**GOBIERNO DE
MÉXICO**

SALUD
SECRETARÍA DE SALUD



Mexico - overview



Inhabitants

119 million people
10.8% Indigenous population


Republic

32 states
Local government and regulations


Language

Spanish
68 different indigenous languages

Mexico – Health System snapshot



HIV Continuum of Care estimates: Mexico 2018



Advances

Diagnosis

- ✓ Simplification of diagnosis algorithms.
- ✓ Publication of HIV Screening Guideline.
- ✓ Projection of needs for diagnosis test.
- ✓ Purchase of central government of HIV diagnosis test (MH).
- ✓ Coordination between CENSIDA and DGE to update epidemiological surveillance manuals (diagnosis algorithms), and update the registry.
- ✓ HIV Detection Bulletin: monitoring of the detection (MH).



Treatment

- ✓ Consolidated purchase of ARV medicines.
- ✓ Needs estimation and centralized purchase of ARV for MH (62% of people in ART).
- ✓ SALVAR system (operating more than 10 years ago).
- ✓ Face-to-face and distance training (Edusida).

Viral Suppression

- ✓ Needs estimation and centralized purchase of monitoring tests (viral load and CD4).
- ✓ Criteria for application of monitoring tests (saving).
- ✓ Resistant committee (CORESAR).
- ✓ Bulletin Attention of people living with HIV and Sector information monitoring.


There is regional variation that we need to understand and address



New HIV Infections

| | 2017 | 2018 |
|--------|------------------------|------------------------|
| Mexico | 11 000 [7900 - 14 000] | 11 000 [7600 - 14 000] |

Strengthening treatment options: New paradigm



Strengthening treatment options: New paradigm

The need of new treatment options was identified

Collaboration
Public Health Sector

Ministry of
Health

Researchers

Clinical leads

Activists

Ministry of
Finance

Procurement saving proposal

Achievements so far

The clinical treatment guideline required an official update

A fast track drug registry approval was required (Biktarvy®)

31 ARV medicines – Estimated reduction of 55% from the baseline costs

23 (72%) regions with initial training

ARV Distribution to regions for the next three months

Three months

Challenges faced

PREVENTION, DETECTION, EARLY TREATMENT

Standardization of the ARV Distribution process

Training, dissemination of information, continue engagement with communities, advocates

Person centered registry – to follow up the outcomes that matter to people living with HIV/AIDS

Many thanks! Muchas Gracias!

